|
|
Gene Symbol |
APOB |
|
Aliases |
FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48 |
|
Entrez Gene ID |
|
|
Gene Name |
Apolipoprotein B |
|
Chromosomal Location |
2p24.1 |
|
HGNC ID |
|
|
Summary |
This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins (LDL), and is the ligand for the LDL receptor. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Dec 2019]
|
|
RefSeq DNA |
|
|
RefSeq mRNA |
|
|
e!Ensembl
|
Gene Ontology (GO)
GO ID |
Ontology |
Function |
Evidence |
Reference |
GO:0008203 |
Biological process |
Cholesterol metabolic process |
IMP |
2563166 |
GO:0009615 |
Biological process |
Response to virus |
IEP |
16548883 |
GO:0010744 |
Biological process |
Positive regulation of macrophage derived foam cell differentiation |
IDA |
17244792, 18322245, 19114110 |
GO:0010884 |
Biological process |
Positive regulation of lipid storage |
IDA |
18322245 |
GO:0010886 |
Biological process |
Positive regulation of cholesterol storage |
IDA |
19114110 |
GO:0030301 |
Biological process |
Cholesterol transport |
IMP |
2563166 |
GO:0034374 |
Biological process |
Low-density lipoprotein particle remodeling |
IMP |
15797858 |
GO:0034379 |
Biological process |
Very-low-density lipoprotein particle assembly |
IC |
15308631 |
GO:0034383 |
Biological process |
Low-density lipoprotein particle clearance |
IMP |
2563166, 15797858 |
GO:0042632 |
Biological process |
Cholesterol homeostasis |
IMP |
2563166 |
GO:0005576 |
Cellular component |
Extracellular region |
HDA |
27068509 |
GO:0005615 |
Cellular component |
Extracellular space |
ISS |
22261194 |
GO:0005737 |
Cellular component |
Cytoplasm |
IDA |
22580899 |
GO:0034359 |
Cellular component |
Mature chylomicron |
IDA |
4363408 |
GO:0034360 |
Cellular component |
Chylomicron remnant |
TAS |
6099394 |
GO:0034361 |
Cellular component |
Very-low-density lipoprotein particle |
IDA |
4363408, 15308631 |
GO:0034361 |
Cellular component |
Very-low-density lipoprotein particle |
TAS |
27477018 |
GO:0034362 |
Cellular component |
Low-density lipoprotein particle |
IDA |
4363408 |
GO:0034362 |
Cellular component |
Low-density lipoprotein particle |
TAS |
27477018 |
GO:0034363 |
Cellular component |
Intermediate-density lipoprotein particle |
IDA |
1917954 |
GO:0042627 |
Cellular component |
Chylomicron |
IDA |
4363408, 8245722 |
GO:0043025 |
Cellular component |
Neuronal cell body |
IDA |
22897442 |
GO:0070062 |
Cellular component |
Extracellular exosome |
HDA |
23533145 |
GO:0070971 |
Cellular component |
Endoplasmic reticulum exit site |
IDA |
27138255 |
GO:0005102 |
Molecular function |
Signaling receptor binding |
IPI |
27477018 |
GO:0005515 |
Molecular function |
Protein binding |
IPI |
8245722, 16203724, 21911577, 22580899, 24447298, 25108285, 26224785, 27138255 |
GO:0005543 |
Molecular function |
Phospholipid binding |
IDA |
7126555 |
GO:0008201 |
Molecular function |
Heparin binding |
IDA |
16233946 |
GO:0035473 |
Molecular function |
Lipase binding |
IPI |
9685400 |
GO:0050750 |
Molecular function |
Low-density lipoprotein particle receptor binding |
IMP |
2563166, 15797858 |
GO:0120020 |
Molecular function |
Intermembrane cholesterol transfer activity |
IMP |
15797858 |
|
Protein Information |
|
Protein Name |
Apolipoprotein B-100, apolipoprotein B (including Ag(x) antigen), apolipoprotein B48 |
|
Function |
Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor |
|
|
|
|
|
UniProt |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000355896 |
|
P61812 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Cardiovascular Diseases |
Coronary heart disease |
|
Digestive System Diseases |
Fatty Liver |
|
Endocrine System Diseases |
PCOS |
|
Immune System Diseases |
Behcet Syndrome |
|
Nutritional and Metabolic Diseases |
Hypobetalipoproteinemias |
3399894, 8792774, 3473077, 21981844, 2022744, 2312735, 2574033, 2843815, 1562615, 2725600, 2614276, 1454832, 1602000, 221546, 1424233, 12551903, 27206948, 24033266, 25741868, 25335495, 24751931, 2567736 |
Hypercholesterolemia |
|
Metabolic Syndrome X |
|
Dyslipidemias |
|
Hyperlipidemia |
|
Hyperlipoproteinemia |
|
Ataxia with vitamin E deficiency |
|
Psychiatric/Brain disorders |
Obstructive Sleep Apnea |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
ApoA-I |
Dyslipidemia |
|
Rotterdam criteria |
Related
|
Chinese-406 patients with PCOS and 342 control women between 17 and 40 years of age |
PCOS patients with dyslipidemia had significantly higher TG/HDL-C ratios, and lower HDL-C and apoA-I levels when compared with the controls or patients without dyslipidemia, and had significantly higher BMIs, fasting insulin concentrations, 2-h insulin and glucose levels, homeostatic model assessment IR, TG levels, LDL-C levels, atherogenic indexes, apoB concentrations and apoB/apoA-I ratios when compared with all of the control women, with or without dyslipidemia and patients without dyslipidemia. |
|
ApoA-I |
Metabolic syndrome |
|
|
Related
|
Chinese-160 adolescent women |
The ApoB/ApoA1 ratio was a good predictive marker of MS and pre-MS in Chinese adolescent women with PCOS |
|
ApoA-I |
Dyslipidemia |
|
|
Related
|
|
A significant finding was the decrease in ApoA1/ApoB ratio among the women with PCOS compared to both controls and obese women. |
|
MCP-1,ApoA-I |
|
|
|
Related
|
|
PCOS obese and non-obese patients had higher serum MCP-1 levels than controls. MCP-1 was correlated with BMI, LH ,TG, ApoB and the ratio of ApoA/ ApoB. |
|
|
Hyperprolactinemia |
|
|
Related
|
|
Patients with hyperPRL + PCOS develop the endocrine disturbances at a younger age, a greater incidence rate of acne, level of prolactin and androstenedione, they have reduced ApoB and increased HOMA-IR. |
|
ApoCIII,ApoCII |
Cardiovascular disease,insulin resistance |
|
|
Related
|
|
Elevated triglycerides and waist circumference predict CVD risk and women with PCOS often have these phenotypes. |
|
|
|